A once-daily regimen of cefazolin (2 g intravenously [iv]) plus probenecid (1 g by mouth) was compared with a once-daily regimen of ceftriaxone (1 g iv) plus oral placebo in a randomized, double-blind equivalence trial of home-based therapy for moderate-to-severe cellulitis in adults. For the assessable recipients of cefazolinprobenecid ( ) and ceftriaxone-placebo ( ), clinical cure occurred at the end of treatment in 86% n p 59 n p 57 and 96% ( ), respectively, and was maintained at 1 month of follow-up in 96% and 91% ( ), P p .11 P p .55 respectively. The mean number of treatment doses (‫ע‬standard deviation) given was similar in the 2 treatment arms ( for cefazolin-probenecid and for ceftriaxone-placebo; ). The median an-6.97 ‫ע‬ 2.6 6.12 ‫ע‬ 2.1 P p .06 tibiotic trough concentrations were 2.35 mg/mL for cefazolin and 15.45 mg/mL for ceftriaxone. Patients in the 2 treatment arms were similar with regard to overall rates of adverse reaction ( ), but nausea was more P p .15 common among those in the cefazolin-probenecid arm ( ). The once-daily regimen of cefazolin-P p .048 probenecid is a cheap, practical, and effective treatment option for moderate-to-severe cellulitis, and it avoids the need to use third-generation cephalosporins in most patients.
an antistaphylococcal penicillin (e.g., flucloxacillin or dicloxacillin) [1] [2] [3] [4] . More recently, regimens with oncedaily dosing schedules, such as ceftriaxone or teicoplanin, have been used for home-based, intravenously administered therapy, to avoid the need for admission to the hospital and to minimize the number of nursing visits needed [5] [6] [7] [8] [9] [10] [11] . However, these latter agents generally have a broader antibacterial spectrum than is clinically required and, therefore, may not be optimal for use as first-line therapy [12] . We recently demonstrated that the first-generation cephalosporin cefazolin (2 g iv b.i.d.) is effective for the home-based treatment of cellulitis, and we suggested that this regimen may be more appropriate than either third-generation ceph-alosporins or glycopeptides [13] . Nevertheless, given the pharmacokinetics of cefazolin, and in an effort to reduce the number of daily doses of cefazolin (and, therefore, the number of home visits), we decided to assess the clinical efficacy of a once-daily regimen of cefazolin in combination with oral probenecid, a drug known to reduce the excretion of cefazolin [14] [15] [16] . Given the widespread use of once-daily regimens of ceftriaxone for the treatment of cellulitis [6, [9] [10] [11] , we compared once-daily cefazolin (2 g iv) plus once-daily probenecid (1 g by mouth [po] ) with once-daily ceftriaxone (1 g iv) plus oral placebo in a randomized, double-blind, multisite trial of home-based treatment of moderate-to-severe cellulitis in adults.
PATIENTS AND METHODS
Patients with moderate-to-severe cellulitis who required intravenous antibiotic therapy and who were considered suitable for home-based "Hospital-in-the-Home" (HITH) therapy were recruited from each of the participating health care centers in Australia (Monash Medical Centre and Dandenong Hospital, Melbourne; Geelong Hospital, Geelong; and Ipswich Hospital, Brisbane). Cellulitis was defined as described elsewhere [13] (i.e., recent onset of soft-tissue erythema associated with signs of infection that included у1 of the following symptoms: pain, swelling, lymphangitis, fever, and ulceration with or without discharge). In each case, cellulitis was severe enough to require patient admission to the hospital and use of intravenous antibiotic therapy, either because of the severity of cellulitis (noted by extensive cellulitis, lymphangitis, and/or ulceration), the presence of sepsis (noted by high fever, rigors, and sweats), or the failure of previous oral or parenteral therapy.
Exclusion criteria included cellulitis that (1) could be suitably treated with oral antibiotic therapy (i.e., mild-to-moderate cellulitis), (2) was nosocomial in origin, and/or (3) was associated with contiguous osteomyelitis, septic shock, or a high likelihood of bacteremia. We also excluded patients who had (1) a known history of allergy to b-lactam antibiotics, (2) a baseline serum creatinine level of 1250 mM (or creatinine clearance of !30 mL/ min), or (3) alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase levels that were more than twice the upper limit of the reference interval, as determined by liver function tests. In addition, we excluded patients who had social circumstances that made them unsuitable for HITH intravenous antibiotic therapy. Thus, the study population comprised patients who would have been routinely suitable for HITH intravenous antibiotic therapy. The study was approved by the ethics committee of each institution, and informed consent was obtained from all participants.
Clinical evaluation at baseline included assessment of patient demographic data, evaluation of signs of systemic and local sepsis (i.e., presence of fever, rigors, and lymphangitis and location and extent of cellulitis), and review of any history of potential predisposing factors. Laboratory tests performed at baseline included blood culture, wound culture (if possible), full blood count (i.e., hemoglobin, WBC count, and platelet count), determination of the serum electrolyte/creatinine level, and liver function tests. Full blood count and electrolyte/creatinine level assessment were repeated if the findings were abnormal at baseline, and blood cultures were repeated if the results were positive at baseline. Radiographic imaging, to detect underlying osteomyelitis, and Doppler ultrasound, to exclude deep venous thrombosis, were performed only if clinically indicated.
Patients were randomized on a 1:1 basis to receive either a once-daily regimen of cefazolin (2 g iv) plus probenecid (1 g given in two 500-mg tablets po; hereafter known as "cefazolinprobenecid") or a once-daily regimen of ceftriaxone (1 g iv) plus placebo (2 tablets po; hereafter known as "ceftriaxoneplacebo"). A 4-per-block randomization schedule was used, in which 2 patients were enrolled in each treatment arm for every 4 sequentially enrolled patients. Each enrolled patient was automatically allocated the next study number for that site. Patients and managing clinicians were blinded to the treatment regimens allocated, and all details regarding randomization, the treatment regimens allocated, and the packaging of probenecid and placebo tablets were managed by the Pharmacy Department at Monash Medical Centre (and then were distributed to participating centers).
Probenecid (500 mg; Merck Sharp & Dohme) and placebo tablets were packaged in identical nondistinctive containers, which were labeled with the appropriate study number, and were placed together with 1 dose of either premixed cefazolin (2 g; Faulding) or ceftriaxone (1 g; Roche), respectively. Initially, all doses of both antibiotics were premixed in 20-mL syringes that were ready for use, and the syringes were wrapped in masking tape to avoid unblinding of clinicians who could detect the difference in color between ceftriaxone (slightly yellow) and cefazolin (clear). However, to allow for overnight enrollments, a number of premixed doses needed to be constantly available in the emergency departments. Because this resulted in considerable wasting of drugs during periods of slow recruitment, the protocol was amended so that the initial after-hours dose was mixed immediately before administration by a staff nurse who was not involved in the study and who maintained blinding for the trial staff. All subsequent doses were premixed in the respective pharmacy departments, and the syringes were wrapped in masking tape (to avoid color detection) and were ready for use. Thus, appropriate blinding of all trial staff was maintained throughout the study.
Once patients had been randomized to the respective treatment arms, the appropriately allocated tablets (two 500-mg tablets of probenecid or 2 tablets of placebo) were administered orally, followed 10-15 min later by intravenous administration of either cefazolin or ceftriaxone, respectively. The duration of intravenous therapy was left to the discretion of the managing physician. Assessment of clinical and microbiologic outcomes. Clinical and microbiologic outcomes were assessed at the end of therapy and at a 1-month follow-up visit. The clinical endpoint definitions for the assessment of cefazolin-probenecid and ceftriaxone-placebo efficacy were as follows. For the endof-therapy assessment, "cure" was defined as complete res- olution of signs and symptoms of soft-tissue infection that was sufficient enough to result in either discontinuation of all antibiotic therapy or a switch to the use of oral agents. For the 1-month follow-up assessment, "cure" was defined as clinical cure with no recurrence of cellulitis at the same site within 1 month of completion of treatment. For the end-oftherapy assessment, "improvement only" was defined as alleviation but incomplete resolution of у2 presenting signs and symptoms, such that improvement in the patient's condition was insufficient to allow for a switch to the use of oral agents after up to 14 days of administration of intravenous therapy; patients who were initially classified as having improvement only were considered to have had treatment failure in all statistical analyses. "Treatment failure" was defined as inadequate improvement that necessitated a change in antibiotic therapy. At the 1-month follow-up assessment, "recurrence" was defined as initial cure followed by recurrence of cellulitis at the same site р1 month after cessation of study treatment. Patients with "indeterminate results" were those who required admission to the hospital or concomitant administration of another antibiotic.
Microbiologic outcome end points at the end of therapy assessment were as follows. "Eradication" was defined as clearance of the principle pathogen(s) from the wound or improvement such that no further cultures could be done. "Persistence" was defined as persistence of any principle pathogens, either at the end of therapy or during the 1-month follow-up period. "Superinfection" was defined as elimination of the principle pathogen(s) but emergence of a new pathogen during treatment.
All adverse reactions were documented. Compliance with oral therapy was directly observed by the study nurses. Serum antibiotic concentrations. When possible, predose ("trough") and 30-60-min postdose ("peak") serum concentrations of cefazolin and ceftriaxone were assessed in study patients at approximately the time of administration of either the fourth or fifth dose. Total serum drug concentrations were determined by means of HPLC (Wakosil C18; SGE Chromatography Products), for which the interassay relative standard deviation was 6% and the minimum quantifiable concentration of each antibiotic was 0.4 mg/mL. The HPLC method was similar to that described elsewhere [13] and was developed on the basis of principles discussed by Paull and Sampson [17] and Miner [18] .
Statistical analysis. The study was designed to assess, with 80% power, whether the 2 treatment regimens had equivalent clinical efficacy, under the assumption that (1) overall treatment efficacy was 85% [6, [9] [10] [11] 19] , (2) the a value was 0.1, and (3) the difference in clinical efficacy between the 2 arms was not less than 15% [20] . The 1:1, 4-block randomization schedule was considered likely to result in very similar numbers of enrollments in each treatment arm. Statistical analyses were performed with either the x 2 test or the t test, as appropriate. was considered to be statistically significant. P ! .05
RESULTS
One hundred thirty-two patients with a total of 134 cases of cellulitis (67 cases in the cefazolin-probenecid arm and 67 cases in the ceftriaxone-placebo arm) were enrolled during a 12-month period that started in August 1999. Baseline patient characteristics were similar for both treatment arms (table 1) . The majority of the subjects (70%) were male, and the mean age of the subjects was 47.6 years. Most patients had either lower-limb or upper-limb cellulitis (73% and 19%, respectively) of 48-72 hours' duration. Baseline symptoms, signs, and predisposing conditions were typical for patients who were considered to have moderate-to-severe cellulitis and who were suitable for home-based therapy: in 55 cases (41%), the patient was febrile; in 44 cases (33%), the patient had lymphangitis; in 25 cases (19%), ulceration; in 130 cases (97%), swelling; in 128 cases (96%), pain; and in 134 cases (100%), soft-tissue erythema. Potential predisposing risk factors for cellulitis were similar for both groups, and more than one-half of all patients in each group had previously received ineffective antibiotic therapy (table 1) .
The results of baseline blood cultures (performed in 122 cases) and wound cultures were similar, with pathogens isolated from wound samples obtained in 34 (72%) of 47 cases (14 [70%] of 20 cases in patients in the cefazolin-probenecid arm and 20 [74%] of 27 cases in patients in the ceftriaxone-placebo arm). Oxacillin-susceptible S. aureus (OSSA) was the most frequently isolated pathogen, either alone (recovered in 21 cases) or with streptococci (in 2 cases) or gram-negative pathogens (in 2 cases). Streptococcus species were isolated in 7 cases, and the patients were infected with other pathogens in 2 cases (methicillin-resistant S. aureus was isolated from one of those patients, and mixed coliforms were isolated from the other). As expected, none of the patients in this study had bacteremia, with the exception of 1 patient, who was subsequently found to have bacterial endocarditis due to Streptococcus mitis and who was withdrawn from the study.
The findings of the assessments of clinical outcome were considered indeterminate for 18 cases in enrolled patients (8 cases in the cefazolin-probenecid arm and 10 in the ceftriaxone-placebo arm; table 2). Thus, clinical outcome was evaluable in 116 cases, with cure being achieved at the end of therapy in 51 (86%) of 59 cases in the cefazolin-probenecid arm and in 55 (96%) of 57 cases in the ceftriaxone-placebo arm ( ). In cases in which it was assessable, microbi-P p .11 ologic outcome was consistent with the clinical response. The duration of study therapy was similar for both groups (mean number of , in the cefazolin-probenecid doses ‫ע‬ SD 6.97 ‫ע‬ 2.6 arm [range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] vs.
in the ceftriaxone-placebo 6.12 ‫ע‬ 2.1 arm [range, 2-11];
). However, the cefazolin-treated P p .06 cases tended to require slightly more doses than did the ceftriaxone-treated cases (median number of doses, 7 in the cefazolin-probenecid arm vs. 6 in the ceftriaxone-placebo arm).
After they completed intravenous therapy, the vast majority of patients completed treatment with 7-10 days of oral antibiotic therapy (generally cephalexin or clindamycin). However, patients in the ceftriaxone-placebo arm had a higher rate of recurrence noted at the 1-month follow-up assessment than did patients in the cefazolin-probenecid arm (5 vs. 2 recurrences, respectively), although 3 of the 51 previously cured patients in the cefazolinprobenecid arm were lost to follow-up (table 2) . Thus, cure rates at the 1-month follow-up assessment were reasonably similar: cure was achieved in 46 (82%) of 56 patients in the cefazolinprobenecid arm and in 50 (85%) of 57 patients in the ceftriaxoneplacebo arm ( ). P p .55 Of the 10 cases in the cefazolin-probenecid arm in which the patient either had treatment failure (8 cases) or a recurrence (2 cases), culture yielded pathogens in only 2 cases. One patient, whose wound culture yielded OSSA, cefazolin-resistant Escherichia coli, and mixed anaerobes, subsequently had persistence of E. coli, which was not surprising. The other patient's baseline wound culture yielded OSSA alone, but none of the subsequent cultures yielded pathogens. Seven cases in the ceftriaxone-placebo arm resulted in either treatment failure (2 cases) or a recurrence (5 cases), but in only 1 case did culture yield pathogenic bacteria. The baseline cultures performed for this patient yielded OSSA alone, and the patient was classified as having experienced treatment failure after she developed a subcutaneous abscess that required surgical drainage after 2 doses of ceftriaxone-placebo were taken.
Serum antibiotic concentrations were assessed in 92 cases (in 47 cases in the cefazolin-probenecid arm and 45 cases in the ceftriaxone-placebo arm). Both trough and peak levels were assessed in 25 cases in the cefazolin-probenecid arm and 28 cases in the ceftriaxone-placebo arm; trough levels alone were assessed in 15 and 12 cases, respectively, and peak levels alone were assessed in 7 and 5 cases, respectively. The results of these assessments are shown in table 2. For an additional 17 cases (8 in the cefazolin-probenecid arm and 9 in the ceftriaxoneplacebo arm), serum samples were obtained for assessment of serum drug levels, but the specimens could not be accurately assessed because of either poor labeling or inappropriate storage.
Clinical outcome did not appear to correlate with serum NOTE. Data are no. of cases, unless otherwise indicated. a Calculated from 38 cases because serum trough concentrations of cefazolin were not detectable (i.e., concentration was !0.4 mg/mL) in 2 cases. b Determined by means of the x 2 test. If the 3 patients who were lost to follow-up were considered to have had recurrence, then . P p .25 c The 6 cases in patients with inappropriate enrollment included 2 cases in patients with osteomyelitis, 1 in a patient with endocarditis, 1 in a patient with mild cellulitis that required only a single dose to achieve cure, 1 in a patient with severe cellulitis who was admitted to the hospital immediately after the first dose, and 1 in a patient with a dermatological condition that initially had been misdiagnosed as cellulitis.
d The 4 cases in patients with inappropriate enrollment included 1 case in a patient with postoperative wound infection (methicillin-resistant Staphylococcus aureus), 1 in a patient with deep venous thrombosis that had been misdiagnosed as cellulitis, 1 in a patient with severe furunculosis, and 1 in a patient with Erythema nodosum infection and sarcoid that had been misdiagnosed as cellulitis. e Patient was admitted to the hospital because of severe nausea, vomiting, and diarrhea on day 4 of therapy; these conditions may have been adverse reactions to therapy. f Probable vasovagal collapse after drug administration (which was not considered to be related to therapy); this resulted in a blow to the patient's head, requiring admission to the hospital. g Two patients were admitted to the hospital because of severe anxiety soon after they received the initial dose. h One patient was concomitantly treated with metronidazole for dental sepsis, and 1 patient was concomitantly treated with ocular chloramphenicol ointment for periorbital cellulitis. i One patient received both cefazolin and ceftriaxone because of an administration error in the pharmacy department, and 1 patient was admitted to the hospital for debridement of a coral wound despite improvement in infection status. antibiotic concentrations. For instance, of the 8 cases in the cefazolin-probenecid arm that resulted in treatment failure, cefazolin trough concentrations were assessed in 5, and the levels were 1.0-85.7 mg/mL. Furthermore, both cases in which serum trough levels of cefazolin were undetectable resulted in clinical cure. Only 1 of the 2 patients in the ceftriaxone-placebo arm who had experienced treatment failure had ceftriaxone levels assessed, but the trough concentration of serum ceftriaxone in this patient was 32.2 mg/mL. Adverse reactions were noted in 21 cases (14 in the cefazolinprobenecid arm and 7 in the ceftriaxone-placebo arm; P p ; table 3). Although the overall rates of adverse reactions in .15 the 2 study groups were similar, patients in the cefazolin-probenecid arm were significantly more likely to complain of nausea and vomiting (11 cases in the cefazolin-probenecid arm vs. 3 in the ceftriaxone-placebo arm;
). One patient in P p .048 the cefazolin-probenecid arm required admission to the hospital because of severe nausea, vomiting, and diarrhea. This patient was notable because her symptoms commenced only after 4 days of therapy and because they resolved spontaneously within 24 h. Although it must be presumed that these symptoms were related to treatment, their timing and resolution are somewhat unusual for a drug-related adverse reaction. In the vast majority of patients, nausea was mild and was either self-limiting or readily controlled with simple oral antiemetics.
DISCUSSION
This double-blind, randomized study assessed patients who are like those routinely treated for moderate-to-severe softtissue cellulitis via HITH programs in Australia. In these patients, once-daily regimens of cefazolin (2 g iv) plus probenecid (1 g po) had clinical and microbiologic efficacies equivalent to those associated with once-daily regimens of ceftriaxone (1 g iv) plus placebo. The duration of treatment and the overall rate of adverse reactions were similar for both regimens. However, cefazolin-probenecid was associated with a higher rate of nausea and vomiting than was ceftriaxoneplacebo ( ); this was probably related to the proben-P p .048 ecid component of the regimen [21] . Nevertheless, these symptoms occurred in a minority of patients and were generally mild, being either self-limited or easily controlled with simple antiemetics. Thus, it would seem unlikely that these symptoms will pose a significant limitation to the future use of cefazolin-probenecid. We did not investigate the efficacy of probenecid administered in a divided dose of 500 mg given twice per day (rather than 1 g q.d.); however, this might be a practical therapeutic option for patients who complain of nausea associated with cefazolin-probenecid [21] .
Serum levels of cefazolin and ceftriaxone were considerably greater than the expected MIC 90 for the common pathogens responsible for most community-acquired cases of cellulitis [15, 22] , with median trough levels of 2.35 mg/mL for cefazolin and 15.45 mg/mL for ceftriaxone. Only 2 patients in the cefazolin-probenecid arm had serum trough levels of cefazolin that were less than the detection limit of our assay (i.e., 0.4 mg/mL); nevertheless, for both patients, cure was achieved with cefazolin-probenecid therapy. Because b-lactam efficacy is thought to be optimal when serum drug concentrations are maintained at levels greater than the MIC value for the infecting organism(s) for a majority (approximately 60%-70%) of the dosing interval, the clinical efficacy of both cefazolinprobenecid and ceftriaxone-placebo is not surprising [15, [23] [24] [25] . At times when serum trough levels are undetectable, efficacy may be related to a number of factors, including postantibiotic effects (for cephalosporins, these are 1-5 h for S. aureus and 0.4-2.3 h for streptococci), postantibiotic leukocyte enhancement, host defense mechanisms, concentrations of drugs within cells, and tissue binding of drug [26] .
It is also notable that the trough concentrations of cefazolin achieved with cefazolin-probenecid are similar to the median trough levels achieved previously with 2 g of cefazolin given intravenously twice per day [13] . Similarly, our data are comparable to those reported by other authors who have assessed once-daily regimens of cefazolin-probenecid, both in terms of serum cefazolin concentrations and clinical efficacy [14, 19] . However, in comparison with the study population reported by Brown et al. [19] , our study population was more homogeneous and had a more complete follow-up.
Although we did not formally assess the financial differences between the use of the cefazolin-probenecid and ceftriaxone-placebo regimens, the substantially lower purchase price of cefazolin-probenecid (approximately $5.70 [$10.50 in Australian dollars]) compared with 1 g of ceftriaxone (approximately $9.70 [$18.00 in Australian dollars]) suggests that cefazolin-probenecid is likely to be a cheaper regimen. In addition, the narrower antibacterial spectrum of cefazolin may make this drug more appropriate than ceftriaxone for treatment of the pathogens likely to be responsible for softtissue cellulitis [3, 12, 15] .
Our study has some potential limitations. First, some may question the severity of cellulitis in our patients and whether they truly had moderate-to-severe disease. Our inclusion criteria were typical of those routinely used to select patients suitable for HITH therapy, and, therefore, by design, we excluded patients who were likely to have bacteremia or require surgical intervention. Given this limitation, we cannot comment on whether cefazolin-probenecid would be appropriate for such severely ill patients. Second, differences in treatment efficacy of !15% may not have been detected in our study because of the size of the study population. Nevertheless, the similarity in outcome, especially at the 1-month follow-up assessment, would suggest that any differences are likely to be rather small, and that a much larger study would be needed to accurately identify any smaller differences.
This study suggests that the once-daily regimen of cefazolin (2 g iv) plus probenecid (1 g po) is a safe, practical, and effective treatment option for the home-based treatment of patients with moderate-to-severe cellulitis.
